Systematic review of pharmacoeconomic models for schizophrenia
Background: Economic models are broadly used in the economic evaluation of antipsychotics in schizophrenia. Our objective was to summarize the structure of these models. Methods: Model-based economic evaluations of antipsychotics in schizophrenia were identified through Medline and Embase. General i...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-01-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20016689.2018.1508272 |
| _version_ | 1797228497280696320 |
|---|---|
| author | Junwen Zhou Aurélie Millier Mondher Toumi |
| author_facet | Junwen Zhou Aurélie Millier Mondher Toumi |
| author_sort | Junwen Zhou |
| collection | DOAJ |
| description | Background: Economic models are broadly used in the economic evaluation of antipsychotics in schizophrenia. Our objective was to summarize the structure of these models. Methods: Model-based economic evaluations of antipsychotics in schizophrenia were identified through Medline and Embase. General information was extracted including analysis type, model type, perspective, population, comparator, outcome, and timeframe. Model-specific structures for decision tree (DT), cohort- and patient-level Markov model (CLMM, PLMM), and discrete-event simulation (DES) models were extracted. Results: A screen of 1870 records identified 79 studies. These were mostly cost-utility analyses (n = 48) with CLMM (n = 32) or DT models (n = 29). They mostly applied payer perspective (n = 68), focused on general schizophrenia for relapse prevention (n = 73), compared pharmacotherapies as first-line (n = 71), and evaluated incremental cost per quality-adjusted life year (QALY) gained (n = 40) with a 1-year (n = 32) or 5-year (n = 26) projection. DT models progressed with the branching points of response, relapse, discontinuation, and adherence. CLMM models transitioned between disease states, whereas PLMM models transitioned between adverse event states with/without disease state. DES models moved forward with times to remission, relapse, psychiatrist visit, and death. Conclusions: A pattern of pharmacoeconomic models for schizophrenia was identified. More subtle structures and patient-level models are suggested for a future modelling exercise. |
| first_indexed | 2024-04-24T14:57:38Z |
| format | Article |
| id | doaj.art-4c663068323b4819889ec3e785a999ca |
| institution | Directory Open Access Journal |
| issn | 2001-6689 |
| language | English |
| last_indexed | 2024-04-24T14:57:38Z |
| publishDate | 2018-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Market Access & Health Policy |
| spelling | doaj.art-4c663068323b4819889ec3e785a999ca2024-04-02T17:10:04ZengMDPI AGJournal of Market Access & Health Policy2001-66892018-01-016110.1080/20016689.2018.15082721508272Systematic review of pharmacoeconomic models for schizophreniaJunwen Zhou0Aurélie Millier1Mondher Toumi2Aix-Marseille UniversityCreativ-CeuticalAix-Marseille UniversityBackground: Economic models are broadly used in the economic evaluation of antipsychotics in schizophrenia. Our objective was to summarize the structure of these models. Methods: Model-based economic evaluations of antipsychotics in schizophrenia were identified through Medline and Embase. General information was extracted including analysis type, model type, perspective, population, comparator, outcome, and timeframe. Model-specific structures for decision tree (DT), cohort- and patient-level Markov model (CLMM, PLMM), and discrete-event simulation (DES) models were extracted. Results: A screen of 1870 records identified 79 studies. These were mostly cost-utility analyses (n = 48) with CLMM (n = 32) or DT models (n = 29). They mostly applied payer perspective (n = 68), focused on general schizophrenia for relapse prevention (n = 73), compared pharmacotherapies as first-line (n = 71), and evaluated incremental cost per quality-adjusted life year (QALY) gained (n = 40) with a 1-year (n = 32) or 5-year (n = 26) projection. DT models progressed with the branching points of response, relapse, discontinuation, and adherence. CLMM models transitioned between disease states, whereas PLMM models transitioned between adverse event states with/without disease state. DES models moved forward with times to remission, relapse, psychiatrist visit, and death. Conclusions: A pattern of pharmacoeconomic models for schizophrenia was identified. More subtle structures and patient-level models are suggested for a future modelling exercise.http://dx.doi.org/10.1080/20016689.2018.1508272Schizophreniapharmacotherapyantipsychoticspharmacoeconomicseconomic modelmodel structure |
| spellingShingle | Junwen Zhou Aurélie Millier Mondher Toumi Systematic review of pharmacoeconomic models for schizophrenia Journal of Market Access & Health Policy Schizophrenia pharmacotherapy antipsychotics pharmacoeconomics economic model model structure |
| title | Systematic review of pharmacoeconomic models for schizophrenia |
| title_full | Systematic review of pharmacoeconomic models for schizophrenia |
| title_fullStr | Systematic review of pharmacoeconomic models for schizophrenia |
| title_full_unstemmed | Systematic review of pharmacoeconomic models for schizophrenia |
| title_short | Systematic review of pharmacoeconomic models for schizophrenia |
| title_sort | systematic review of pharmacoeconomic models for schizophrenia |
| topic | Schizophrenia pharmacotherapy antipsychotics pharmacoeconomics economic model model structure |
| url | http://dx.doi.org/10.1080/20016689.2018.1508272 |
| work_keys_str_mv | AT junwenzhou systematicreviewofpharmacoeconomicmodelsforschizophrenia AT aureliemillier systematicreviewofpharmacoeconomicmodelsforschizophrenia AT mondhertoumi systematicreviewofpharmacoeconomicmodelsforschizophrenia |